ISRCTN77772144已完成不适用
Prospective, multicentre, randomised, double-blinded and placebo-controlled clinical trial on the efficacy and safety of clonidine as a co-medication in analgesia and sedation of long-term-ventilated neonates and infants
niversity Hospital of Cologne (Germany)0 个研究点目标入组 210 人开始时间: 2004年1月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 210
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Term-newborns, infants =24th month of life. Expected duration of ventilation: 6 days.
排除标准
- •1. Any contraindication to clonidine application:
- •1.1 Hypotone, catecholamine and volume-refractory circulation problems
- •1.2 Dysfunction of cardiac excitation, like atrioventricular blocks second and third degree, sick sinus syndrome
- •1.3 Relevant circulation-effective bradycardias
- •1.4 Hypersensitivity against clonidine or any other component of the drug
- •2. Any circumstances, which make the evaluation of pain sensation impossible (for example coma, severe brain injury, hypoxic-ischemic brain injury, neurological or neuromuscular illnesses, application of muscle relaxants (except short-time application for intubation and application at the first day of ventilation)
- •3. Newborns: anamnestic evidence for drug abuse of the mother (for example psychopharmaca, opioids)
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to assess the efficacy and safety of a vaccine for grasses and olive tree allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738CTIS2024-514525-34-00Inmunotek S.L.180
进行中（未招募）
1 期
Clinical trial to asses the efficacy and safety of a vaccine for grasses and cupressaceae allergyAetiological treatment of moderate-severe intermitent or persistent allergic rhinitis/rhinoconjunctivitis with or without controlled mild-moderate intermittent or persistent allergic asthmaMedDRA version: 27.0Level: LLTClassification code: 10070526Term: Grass allergy Class: 10021428MedDRA version: 26.0Level: LLTClassification code: 10034382Term: Perennial allergic rhinitis Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10001728Term: Allergic rhinoconjunctivitis Class: 10015919MedDRA version: 21.1Level: LLTClassification code: 10001705Term: Allergic asthma Class: 10038738MedDRA version: 20.0Level: LLTClassification code: 10036019Term: Pollen allergy Class: 10021428CTIS2024-514524-16-00Inmunotek S.L.180
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy of a 0.005% estriol vaginal gel in the prevention of recurrent urinary tract infections in postmenopausal women with vaginal atrophy.Recurrent Urinary Tract Infection (UTI) in postmenopausal women with vaginal atrophy.MedDRA version: 20.0Level: LLTClassification code 10038140Term: Recurrent urinary tract infectionSystem Organ Class: 100000004862EUCTR2018-001481-42-ESITF RESEARCH PHARMA S.L.U.120
进行中（未招募）
1 期
Dose-response study of efficacy and safety of Botulinum toxin type A to treat spasticity of the leg(s) in cerebral palsyower limb spasticity due to cerebral palsyMedDRA version: 17.1Level: LLTClassification code 10058977Term: Spastic paresisSystem Organ Class: 100000004852EUCTR2012-005054-30-SKMerz Pharmaceuticals GmbH300
进行中（未招募）
1 期
Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety phase 3 study of an intravenous human plasma-derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacksacute hereditary angioedema attacksMedDRA version: 20.0Level: LLTClassification code: 10075280Term: Hereditary angioedema attack Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080960Term: Hereditary angioedema type II Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080957Term: Hereditary angioedema C1 inhibitor deficiency Class: 10010331MedDRA version: 21.0Level: LLTClassification code: 10080956Term: Hereditary angioedema type I Class: 10010331CTIS2023-503507-29-00Octapharma Pharmazeutika Produktionsgesellschaft mbH124